Gemphire Therapeutics, based in Northville, Michigan, was founded in 2014 and is committed to addressing the unmet medical need of dyslipidemia patients. Their drug candidate, Gemcabene, is an oral once-daily medication designed to lower LDL cholesterol levels. The company aims to help patients who are unable to achieve optimal cholesterol levels with statins or other treatments. In 2019, Gemphire Therapeutics was acquired by NeuroBo Pharmaceuticals.